MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ajh.70425

Медицинская библиотека · American journal of hematology · 2026

Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.

Lim Kenneth J C, Kumar Shaji, Parrondo Ricardo, Chhabra Saurabh, Tan Melinda, Dooley Katharine, Corraes Andre De Menezes Silva, Gertz Morie, Hwa Lisa, Stephens Haily, Kapoor Prashant, Kourelis Taxiarchis, Warsame Rahma, Cook Joselle, Binder Moritz, Abdallah Nadine, Bergsagel P Leif, Yadav Udit, Wiedmeier-Nutor J Erin, Geyer Susan, Rajkumar S Vincent, Ailawadhi Sikander, Fonseca Rafael, Lin Yi, Zanwar Saurabh

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

Ciltacabtagene autoleucel (cilta-cel) has demonstrated excellent efficacy and long-term disease control in patients with relapsed/refractory multiple myeloma (RRMM). However, a proportion of patients experience early treatment failures. We investigated clinical factors associated with early progression or death (within 12 months) in patients with RRMM receiving standard-of-care cilta-cel across the three Mayo clinic centers. Patients with a follow-up of at least 12 months or progression or death within 12 months from infusion were included. Of the patients with early treatment failure (n = 52), 69% had progressive disease and 31% had a non-relapse mortality (NRM) event. In patients without early treatment failure (n = 164), 13% of events were NRM. Among pretreatment factors, prior BCMA-directed therapy, presence of extramedullary disease and a CAR-HEMATOTOX score of ≥ 2 were independent predictors of early progression or death. The utilization of cilta-cel in earlier lines of treatment (1-3 vs. 4 or more) demonstrated comparable PFS (12-month PFS 73% vs. 77%, p = 0.94). Measurable residual disease positivity in the bone marrow at 3 months (11/197 patients) identified a small but high-risk group with an increased risk of early treatment failure (OR 5.68; p = 0.012). Patients with less than a complete response on a FDG PET/CT at 3 months also had an increased risk of early treatment failure (OR 11.8; p < 0.0001). Our findings may help identify patients at high-risk for early adverse outcomes despite receiving highly effective therapy, and support consideration of novel therapeutic strategies within a clinical trial setting.

Для цитирования: Lim Kenneth J C, Kumar Shaji, Parrondo Ricardo, Chhabra Saurabh, Tan Melinda, Dooley Katharine, Corraes Andre De Menezes Silva, Gertz Morie, Hwa Lisa, Stephens Haily, Kapoor Prashant, Kourelis Taxiarchis, Warsame Rahma, Cook Joselle, Binder Moritz, Abdallah Nadine, Bergsagel P Leif, Yadav Udit, Wiedmeier-Nutor J Erin, Geyer Susan, Rajkumar S Vincent, Ailawadhi Sikander, Fonseca Rafael, Lin Yi, Zanwar Saurabh. Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.. American journal of hematology. 2026. DOI: 10.1002/ajh.70425.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.